NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

Data To Be Presented At AAIC In July

 
• By Mandy Jackson
  
If NewAmsterdam pursues further testing, obicetrapib could offer an oral drug for Alzheimer's disease (Shutterstock)

More from Clinical Trials

More from Scrip